Skip to Main Content

Paper Details

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
JAMA Oncol
9
2023
BC, DAPHNe, ERBB2, ERBB2 (formerly, ERBB2+ BC, ERBB2-Positive Breast Cancer, ERBB2-enriched subtype, HER2, HER2)-positive breast cancer, HER2DX, Paclitaxel, Patients, Pertuzumab, Trastuzumab, pCR, paclitaxel, participants, patients, pertuzumab, trastuzumab, tumor, tumor biopsy samples, women
Author NameAffiliation
Ian E KropDana-Farber Cancer Institute
Ian E KropNow with Yale Cancer Center
Ian E KropDana-Farber Brigham Cancer Center
Ian E KropHarvard Medical School
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Joel S ParkerLineberger Comprehensive Cancer Center, University of North Carolina
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina
Eric P WinerDana-Farber Cancer Institute
Eric P WinerHarvard Medical School
Eric P WinerDana-Farber Brigham Cancer Center
Eric P WinerNow with Yale Cancer Center
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyHarvard Medical School
Sara M TolaneyDana-Farber Brigham Cancer Center
  • 1 - 14

Datasets

Release 1.2